Baidu
map

CJON:实施社区护理服务,提高癌症患者生存质量—一篇文献综述

2015-07-11 MedSci MedSci原创

背景:随着科技的进步和医疗条件的改善,癌症患者的生存率得以提高。因为许多癌症患者居住在社区里,因此我们需要采取一些以社区为基础的护理措施和活动来帮助癌症患者和他们的家庭。目的:该实验的目的是告知护士和研究学者,当今以事实为基础的社区护理干预措施和服务的现状,并为社区的癌症患者提供护理指导。方式:我们采用文献检索的方式搜索了关于为癌症患者提供护理干预措施的文章。一共选取了15篇文章用于讨论分析,并将

背景:
随着科技的进步和医疗条件的改善,癌症患者的生存率得以提高。因为许多癌症患者居住在社区里,因此我们需要采取一些以社区为基础的护理措施和活动来帮助癌症患者和他们的家庭。


目的:
该实验的目的是告知护士和研究学者,当今以事实为基础的社区护理干预措施和服务的现状,并为社区的癌症患者提供护理指导。

方式:
我们采用文献检索的方式搜索了关于为癌症患者提供护理干预措施的文章。一共选取了15篇文章用于讨论分析,并将其分为两类:女性乳腺癌患者和其他所有类型的癌症患者。

结果:
通过对文献进行综合分析,我们发现,,以社区为基础的护理干预和护理指导是有利于提高癌症患者的生活质量的,并能减少癌症患者出现相应的并发症,减少了他们疾病的痛苦。运动,精神支持和鼓励、以家庭为中心的护理干预措施和健康宣教,对其子女和配偶今后的发展都大有裨益,并且可以提高他们的生活质量。这些发现为肿瘤科护士和其他研究方向的学者起到一定的指导性作用,鼓励肿瘤科护士和医生在社区集中实施护理措施和健康宣教。同时,我们需要对社区癌症患者进行更进一步的研究,以获得更高质量、更划算的、更多样本、多方协作的以社区为基础的发现,提高肿瘤护理服务,提高患者的生活质量,更好地实现优质护理,减轻病人和家人的痛苦。

原始出处:

Roux G, Solari-Twadell A, Ackers S.Community interventions for survivors and their families: a literature synthesis. Clin J Oncol Nurs. 2015 Jun 1;19(3):E63-9.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1749048, encodeId=0a521e490485f, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Wed May 25 13:36:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801529, encodeId=ccfc180152931, content=<a href='/topic/show?id=ac00e40652a' target=_blank style='color:#2F92EE;'>#社区护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74065, encryptionId=ac00e40652a, topicName=社区护理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Oct 05 07:36:00 CST 2015, time=2015-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932527, encodeId=d1ff193252e98, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Sep 13 07:36:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927261, encodeId=d7b3192e261b9, content=<a href='/topic/show?id=b8905e89914' target=_blank style='color:#2F92EE;'>#文献综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57899, encryptionId=b8905e89914, topicName=文献综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri May 20 12:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289467, encodeId=4688128946e16, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395621, encodeId=8e941395621d1, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554373, encodeId=76a615543e3ff, content=<a href='/topic/show?id=9ebb55993a8' target=_blank style='color:#2F92EE;'>#护理服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55993, encryptionId=9ebb55993a8, topicName=护理服务)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f56214527680, createdName=liye789132256, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1749048, encodeId=0a521e490485f, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Wed May 25 13:36:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801529, encodeId=ccfc180152931, content=<a href='/topic/show?id=ac00e40652a' target=_blank style='color:#2F92EE;'>#社区护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74065, encryptionId=ac00e40652a, topicName=社区护理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Oct 05 07:36:00 CST 2015, time=2015-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932527, encodeId=d1ff193252e98, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Sep 13 07:36:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927261, encodeId=d7b3192e261b9, content=<a href='/topic/show?id=b8905e89914' target=_blank style='color:#2F92EE;'>#文献综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57899, encryptionId=b8905e89914, topicName=文献综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri May 20 12:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289467, encodeId=4688128946e16, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395621, encodeId=8e941395621d1, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554373, encodeId=76a615543e3ff, content=<a href='/topic/show?id=9ebb55993a8' target=_blank style='color:#2F92EE;'>#护理服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55993, encryptionId=9ebb55993a8, topicName=护理服务)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f56214527680, createdName=liye789132256, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1749048, encodeId=0a521e490485f, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Wed May 25 13:36:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801529, encodeId=ccfc180152931, content=<a href='/topic/show?id=ac00e40652a' target=_blank style='color:#2F92EE;'>#社区护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74065, encryptionId=ac00e40652a, topicName=社区护理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Oct 05 07:36:00 CST 2015, time=2015-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932527, encodeId=d1ff193252e98, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Sep 13 07:36:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927261, encodeId=d7b3192e261b9, content=<a href='/topic/show?id=b8905e89914' target=_blank style='color:#2F92EE;'>#文献综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57899, encryptionId=b8905e89914, topicName=文献综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri May 20 12:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289467, encodeId=4688128946e16, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395621, encodeId=8e941395621d1, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554373, encodeId=76a615543e3ff, content=<a href='/topic/show?id=9ebb55993a8' target=_blank style='color:#2F92EE;'>#护理服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55993, encryptionId=9ebb55993a8, topicName=护理服务)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f56214527680, createdName=liye789132256, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1749048, encodeId=0a521e490485f, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Wed May 25 13:36:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801529, encodeId=ccfc180152931, content=<a href='/topic/show?id=ac00e40652a' target=_blank style='color:#2F92EE;'>#社区护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74065, encryptionId=ac00e40652a, topicName=社区护理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Oct 05 07:36:00 CST 2015, time=2015-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932527, encodeId=d1ff193252e98, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Sep 13 07:36:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927261, encodeId=d7b3192e261b9, content=<a href='/topic/show?id=b8905e89914' target=_blank style='color:#2F92EE;'>#文献综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57899, encryptionId=b8905e89914, topicName=文献综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri May 20 12:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289467, encodeId=4688128946e16, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395621, encodeId=8e941395621d1, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554373, encodeId=76a615543e3ff, content=<a href='/topic/show?id=9ebb55993a8' target=_blank style='color:#2F92EE;'>#护理服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55993, encryptionId=9ebb55993a8, topicName=护理服务)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f56214527680, createdName=liye789132256, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1749048, encodeId=0a521e490485f, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Wed May 25 13:36:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801529, encodeId=ccfc180152931, content=<a href='/topic/show?id=ac00e40652a' target=_blank style='color:#2F92EE;'>#社区护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74065, encryptionId=ac00e40652a, topicName=社区护理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Oct 05 07:36:00 CST 2015, time=2015-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932527, encodeId=d1ff193252e98, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Sep 13 07:36:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927261, encodeId=d7b3192e261b9, content=<a href='/topic/show?id=b8905e89914' target=_blank style='color:#2F92EE;'>#文献综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57899, encryptionId=b8905e89914, topicName=文献综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri May 20 12:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289467, encodeId=4688128946e16, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395621, encodeId=8e941395621d1, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554373, encodeId=76a615543e3ff, content=<a href='/topic/show?id=9ebb55993a8' target=_blank style='color:#2F92EE;'>#护理服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55993, encryptionId=9ebb55993a8, topicName=护理服务)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f56214527680, createdName=liye789132256, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1749048, encodeId=0a521e490485f, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Wed May 25 13:36:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801529, encodeId=ccfc180152931, content=<a href='/topic/show?id=ac00e40652a' target=_blank style='color:#2F92EE;'>#社区护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74065, encryptionId=ac00e40652a, topicName=社区护理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Oct 05 07:36:00 CST 2015, time=2015-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932527, encodeId=d1ff193252e98, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Sep 13 07:36:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927261, encodeId=d7b3192e261b9, content=<a href='/topic/show?id=b8905e89914' target=_blank style='color:#2F92EE;'>#文献综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57899, encryptionId=b8905e89914, topicName=文献综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri May 20 12:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289467, encodeId=4688128946e16, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395621, encodeId=8e941395621d1, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554373, encodeId=76a615543e3ff, content=<a href='/topic/show?id=9ebb55993a8' target=_blank style='color:#2F92EE;'>#护理服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55993, encryptionId=9ebb55993a8, topicName=护理服务)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f56214527680, createdName=liye789132256, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1749048, encodeId=0a521e490485f, content=<a href='/topic/show?id=b7c069022a5' target=_blank style='color:#2F92EE;'>#生存质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69022, encryptionId=b7c069022a5, topicName=生存质量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ad36217923, createdName=kksonne, createdTime=Wed May 25 13:36:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801529, encodeId=ccfc180152931, content=<a href='/topic/show?id=ac00e40652a' target=_blank style='color:#2F92EE;'>#社区护理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74065, encryptionId=ac00e40652a, topicName=社区护理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Oct 05 07:36:00 CST 2015, time=2015-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932527, encodeId=d1ff193252e98, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Sep 13 07:36:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927261, encodeId=d7b3192e261b9, content=<a href='/topic/show?id=b8905e89914' target=_blank style='color:#2F92EE;'>#文献综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57899, encryptionId=b8905e89914, topicName=文献综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Fri May 20 12:36:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289467, encodeId=4688128946e16, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395621, encodeId=8e941395621d1, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554373, encodeId=76a615543e3ff, content=<a href='/topic/show?id=9ebb55993a8' target=_blank style='color:#2F92EE;'>#护理服务#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55993, encryptionId=9ebb55993a8, topicName=护理服务)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f56214527680, createdName=liye789132256, createdTime=Mon Jul 13 12:36:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]

相关资讯

JNCI:科学家发现新淋巴结转移灶不会形成新生血管

有研究表明使用抗血管生成药物阻断新血管生长对于提高一些癌症的治疗效果具有一定作用,但临床数据表明这些药物在抑制新转移灶形成方面发挥的作用并不尽如人意。近日,来自美国马萨诸塞总医院癌症中心的研究人员发现了导致这一结果发生的一个可能原因,相关研究结果发表在国际学术期刊Journal of the National Cancer Institute上。   在这项研究中,研究人员发现癌细胞

Cancer Cell:与恶魔共舞的活性氧自由基

低浓度的活性氧自由基(ROS)可以触发癌细胞的产生,但是因为这些氧自由基的存在,癌细胞也变得更加脆弱。在最新一期的Cancer cell发表了一篇评论文章中,Harris和他的同事们,通过增加普通细胞内的氧自由基应激压力,发现可以抑制癌细胞的产生和肿瘤的发展。因此,有策略地针对细胞内的抗氧化自由基系统,可以为癌症治疗提供新的方向。 低浓度的活性氧自由基可以改变部分蛋白的结构。这些氧自由基可作为一

eLife:科学家揭开抑癌又促癌扩散的双刃剑蛋白的神秘面纱

来自加利福尼亚大学的研究人员近日研究发现了一种新型的细胞信号通路,该通路或许可以有效控制结直肠癌的发生和发展,该通路中的一种关键蛋白被认为可以有效预测结直肠癌患者的癌症生存率,相关研究刊登于国际杂志eLife上。 这种特殊蛋白名为“散乱蛋白”,其富含亮氨酸残基或Daple基因,机体中几乎所有的健康细胞都会产生散乱蛋白,而且该蛋白可以帮助不同组织中的细胞来进行多种生物学过程的协调,比如器官发育和维

ONF:患者和父母——养育未成年子女的同时如何应对自身癌症?

目标:该研究对患有癌症的父母及其未成年子女进行调查,目的是探究父母的患病经历,以及他们在面对疾病和家庭相关的挑战和问题时的处理方案,以及支持性策略。设计:该研究为定性、描述性研究,并采用半结构式音频访谈。研究地点在加拿大魁北克蒙特利尔地区麦克里尔大学附属医院的一个大型癌症护理研究中心进行。参与人员为年龄范围在33-67岁、于去年首次罹患癌症并在癌症护理中心接受治疗的5位母亲和7位父亲。这些参与的家

癌症和慢性病治疗新策略

雷帕霉素属大环内酯类抗生素和免疫抑制剂,与FK506的结构相似,可阻断T淋巴细胞及其他细胞由G1期至S期的进程,从而发挥免疫抑制效应。起初雷帕霉素被研究作为低毒性的抗真菌药物,1977年发现雷帕霉素具有免疫抑制作用,1989年开始把雷帕霉素作为治疗器官移植的排斥反应的新药进行试用,目前III期临床试验正在进行之中。从临床应用来看,雷帕霉素有很好的抗排斥作用,且与环孢霉素A和FK506等免疫抑制剂有

研究靠谱吗?高影响力癌症研究可再现性项目引全球关注

美非营利机构计划对全球50篇重要癌症生物学研究成果进行可再现性研究,这一举动引发广泛争议。图片来源:DAVIDE BONAZZI2013年10月,Richard Young收到一封措辞有礼但语气坚定的邮件。发件人是“调查癌症生物学研究可再现性”研究小组的成员。Young是美国麻省理工学院一名生物学家,他之所以收到这封邮件,是因为2012年他曾在《细胞》杂志发表了一篇关于“一种叫作原癌基因的蛋白

Baidu
map
Baidu
map
Baidu
map